Business
Final Results & Notice of AGM
OptiBiotix Health plc reported a 34% increase in revenue to £1.17 million for the twelve months ended December 31, 2025, with gross profit rising 85% to £614,000 and the gross profit margin improving to 53%. Operating costs remained stable at just under £2.7 million, while the cash balance grew to £1.04 million. The company also holds investments in ProBiotix Health Plc and SkinBioTherapeutics Plc with an aggregate market value of £6.45 million as of December 31, 2025. Significant developments include the launch of SlimBiome® in Hydroxycut and a distribution agreement with a major weight management company, alongside expansion in Asia with 17 products launched and 74 customer projects underway. Post-period, the company secured a substantial SlimBiome order from Taiwan and experienced a record start to 2026 with over £800,000 in orders received in January. Disclaimer*
About this update from Optibiotix Health Plc
OptiBiotix Health plc ("OptiBiotix" or the "Company" or the "Group") Final results and Notice of Annual General Meeting OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitute announces its audited results for the 12 months ended 31 December 2025. Highlights · Revenues up 34% to £1.17m (2024: £870k) with £212k of orders received in 2025 not included and carried forward for delivery in 2026 · Gross profit up 85% to £614k (2024: £331k) · Gross profit margin increased to 53% (2024: 38%) · Operating costs (including selling, R&D and patent costs but excluding non-cash share based payments) are slightly up at just under £2.7m (2024: £2.6m) · Cash balance of £1.04m (2024: £739k) · Holdings in ProBiotix Health Plc ("PBX") and SkinBioTherapeutics Plc ("SBTX") with an aggregate market value of £6.45m as of 31 December 2025. · Launch of SlimBiome® in Hydroxycut, which markets itself as the No. 1 selling weight loss supplement brand in the United States of America ("USA") · Signing of a distribution agreement with a well-known direct selling weight management company with a first order received in H2 2025 with product launch scheduled for H1 2026 · Growing list of new customers in Asia with 17 products launched and 74 customer projects at various stages of development across six different countries. · Territories outside the UK now represent 73% of revenue (2024:63%) with Asia increasing by 182% to £268k from £95k in 2024 · Introduction of an optimised enzyme-based production process for SweetBiotix that delivers much higher yields, a purer and better-tasting product, and reduces ingredient and production costs · The Company ended 2025 with a balance sheet of £6.8m (2024: £9.0m), a strong cash position of £1.04m (2024: £739K), no debt and a growing pipeline of new customers Post period end · Twenty-four metric tonnes (24mt) SlimBiome order from Meelung Trading, Taiwan to be delivered at approximately three-month intervals throughout 2026 with payment already received for the first 12mt. ·...
View stock analysis, news, and events for Optibiotix Health Plc